A revised model for mitochondrial dysfunction in Duchenne muscular dystrophy.
Journal
European journal of translational myology
ISSN: 2037-7452
Titre abrégé: Eur J Transl Myol
Pays: Italy
ID NLM: 101576208
Informations de publication
Date de publication:
17 Sep 2021
17 Sep 2021
Historique:
received:
03
08
2021
accepted:
12
09
2021
pubmed:
18
9
2021
medline:
18
9
2021
entrez:
17
9
2021
Statut:
epublish
Résumé
We recently identified a signaling pathway that links the upregulation of miR-379 with a mitochondrial response in dystrophic muscle. In the present commentary, we explain the significance that this pathway may have in mitochondrial dysfunction in Duchenne muscular dystrophy (DMD). We identified the upregulation of miR-379 in the serum and muscles of DMD animal models and patients. We found that miR-379 is one of very few miRNAs whose expression was normalized in DMD patients treated with glucocorticoid. We identified EIF4G2 as a miR-379 target, which may promote mitochondrial oxidative phosphorylation (OxPhos) in the skeletal muscle. We found enriched EIF4G2 expression in oxidative fibers, and identified the mitochondrial ATP synthase subunit DAPIT as a translational target of EIF4G2. The identified signaling cascade, which comprises miR-379, EIF4G2 and DAPIT, may link the glucocorticoid treatment in DMD to a recovered mitochondrial ATP synthesis rate. We propose an updated model of mitochondrial dysfunction in DMD.
Identifiants
pubmed: 34533019
doi: 10.4081/ejtm.2021.10012
pmc: PMC8495359
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2013;8(2):e55281
pubmed: 23418438
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):2988-2993
pubmed: 29440398
Eur J Histochem. 2012 May 22;56(2):e18
pubmed: 22688299
Neurology. 1975 Dec;25(12):1111-20
pubmed: 1105232
J Clin Med. 2020 Feb 14;9(2):
pubmed: 32075145
Cell Metab. 2018 May 01;27(5):1026-1039.e6
pubmed: 29606596
J Med Genet. 2014 Aug;51(8):495-501
pubmed: 24891339
Autophagy. 2016;12(2):369-80
pubmed: 26566717
Pharmacol Res. 2016 Nov;113(Pt A):563-573
pubmed: 27697642
Lancet. 1976 Mar 27;1(7961):672-4
pubmed: 73643
Sci Rep. 2016 Sep 16;6:33362
pubmed: 27634466
Sci Rep. 2020 Jun 4;10(1):9139
pubmed: 32499563
Neurology. 2011 Jan 18;76(3):219-26
pubmed: 21178099
J Biol Chem. 2010 Jun 18;285(25):19483-90
pubmed: 20382743
Nat Rev Dis Primers. 2021 Feb 18;7(1):13
pubmed: 33602943
Cell Stem Cell. 2016 Feb 4;18(2):214-28
pubmed: 26627594
Neurology. 1998 Jul;51(1):1 and 10 pages following
pubmed: 9674765
Trends Genet. 2008 Jun;24(6):306-16
pubmed: 18471925
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17016-21
pubmed: 17942673
Genomics. 2006 Feb;87(2):225-35
pubmed: 16309881
Hum Mol Genet. 2018 Oct 1;27(19):3305-3312
pubmed: 29917077
PLoS One. 2010 Jan 08;5(1):e8638
pubmed: 20072617
PLoS One. 2009 Oct 09;4(10):e7399
pubmed: 19816583
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13627-32
pubmed: 26487685
Clin Pediatr Endocrinol. 2008;17(4):103-11
pubmed: 24790371
Sci Rep. 2017 Dec 12;7(1):17417
pubmed: 29234032
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):677-693
pubmed: 34037326
iScience. 2018 Aug 31;6:83-91
pubmed: 30240627
Genes Dev. 2016 Sep 1;30(17):1991-2004
pubmed: 27664238
Nucleic Acids Res. 2019 Mar 18;47(5):2205-2215
pubmed: 30657980
FASEB J. 2014 Feb;28(2):548-68
pubmed: 24249639
Am J Pathol. 2014 Nov;184(11):2885-98
pubmed: 25194663
Physiol Rev. 2016 Jan;96(1):253-305
pubmed: 26676145
Front Physiol. 2021 Apr 09;12:647010
pubmed: 33897454
J Biol Chem. 2011 Jun 10;286(23):20292-6
pubmed: 21345788
Med Hypotheses. 2015 Dec;85(6):1021-33
pubmed: 26365249
Am J Med Genet A. 2004 Sep 15;130A(1):88-91
pubmed: 15368501
Nat Genet. 2012 Mar 04;44(4):398-405, S1-2
pubmed: 22387999
Am J Med Genet A. 2004 Jun 1;127A(2):167-71
pubmed: 15108205
Development. 2020 Sep 2;147(21):
pubmed: 32878913
Mol Biol Evol. 2016 Sep;33(9):2232-47
pubmed: 27189568
Acta Myol. 2012 May;31(1):9-15
pubmed: 22655511
J Cardiovasc Dev Dis. 2018 Jul 10;5(3):
pubmed: 29996488